Talaromyces marneffei (T. marneffei, also known as Penicillium marneffei) is a regional opportunistic fungus that mainly causes life-threatening disseminated infection of the acquired immunodeficiency syndrome (AIDS) that causes epidemics in Southeast Asia and South China. The thermally dimorphic fungi invade mainly the skin, lungs, liver, spleen, lymph nodes and the circulatory system. Central nervous system (CNS) infection is extremly rare. At present, there are only 22 AIDS-associated cases T. CNS infection of marneffei and two sporadic cases of non-AIDS patients with T. Infection with CNS marneffei has been documented worldwide. These two patients who had not had AIDS suffered from T. Marneffei CNS infections with no underlying immune defects. AIDS-associated CNS infection clinical characteristics T. Marneffei are also unaccounted for. Here, we performed a retrospective study of ten patients in southwestern China who were affected by T infection with AIDS-associated CNS. Marneffei characterizing the clinical symptoms and effective diagnosis of the disease. Distributed to T. Infection with marneffei mainly involves circulatory, respiratory and digestive systems, leading to common clinical symptoms including fever, cough, abdominal pain, weight loss, anemia, and skin lesions.. However, CNS involvement is rare. In this study, besides the common symptoms such as fever, anemia and skin lesions, all the patients predominantly showed initial presenting symptoms or manifestations of CNS infection, including headache, vomiting, dizziness and dyskinesia or fatigue. Talaromyces marneffei primarily infects immunocompromised individuals such as AIDS patients, especially those with CD4 + T cell counts < 50 cells / μL. Studies have found that in HIV-associated cryptococcal meningitis, CD4 + T cells were usually below 50 cells / μL, and that some severe cases even had levels below 30 cells / μL. The recommended treatment for AIDS-associated T is currently under way. Intravenous marneffei non-CNS infection is AmB for 2 weeks followed by oral itraconazole (400 mg / day) for 10 weeks, followed by oral itraconazole (200 mg / day) as maintenance therapy, with ART starting as soon as possible. This review tells about the future scope of the new invention towards the field of HIV /AIDS and their medicinal treatment. People who are interested can send their article towards our journal for publication through this link https://www.scholarscentral.org/submissions/hiv-aids-research.html.